Eprodisate slows the progression of renal disease in patients with AA amyloidosis.
Eprodisate slows the progression of renal disease in patients with AA amyloidosis.
复制标题
依普罗地酯可减缓 AA 淀粉样变性患者肾脏疾病的进展。
DOI：
10.1038/ncpneph0615
复制
发表时间：
2007
影响因子：
--
通讯作者：
Leung,Nelson
中科院分区：
文献类型：
--
作者：
Rule,AndrewD;Leung,Nelson
BackgroundEprodisate is a new therapeutic agent that is designed to inhibit the amyloid deposition responsible for organ dysfunction in amyloid A (AA) amyloidosis.ObjectiveTo determine the efficacy and safety of eprodisate for the treatment of renal disease associated with AA amyloidosis.DesignPatients with AA amyloidosis and renal involvement were enrolled from 13 countries for this randomized, double-blind, placebo-controlled trial. Renal involvement was defined as urine protein excretion> 1 g/24 h or creatinine clearance< 60 ml/min, observed on two occasions at least 1 week apart and within the 3 months preceding study entry. Exclusion criteria included nonamyloid kidney disease, diabetes mellitus, and creatinine clearance< 20 ml/min.
